Breaking News Instant updates and real-time market news.

MSTX

Merged into SVRA

$0.08

-0.0062 (-7.19%)

, PHG

Philips

$28.84

-0.13 (-0.45%)

08:06
10/17/16
10/17
08:06
10/17/16
08:06

Mast Therapeutics announces supply agreement with Philips

Mast Therapeutics (MSTX) announced that its wholly-owned subsidiary, Aires Pharmaceuticals, has entered into a collaborative agreement with Philips Respironics, the sleep and respiratory care business of Royal Philips (PHG) related to the supply of Philips' I-neb Adaptive Aersol Delivery devices and related consumables for the nebulized delivery of the company's lead product candidate, AIR001, a sodium nitrite solution for intermittent inhalation. The I-neb handheld AAD system is a small, portable and virtually silent vibrating mesh technology nebulizer system designed to deliver more precise, reproducible doses of medication faster than conventional jet or ultrasonic nebulizers.

MSTX

Merged into SVRA

$0.08

-0.0062 (-7.19%)

PHG

Philips

$28.84

-0.13 (-0.45%)

MSTX Merged into SVRA
$0.08

-0.0062 (-7.19%)

11/12/15
11/12/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Accuray (ARAY) initiated with a Sell at Citi... Becton Dickinson (BDX) initiated with a Neutral at Citi... Boston Scientific (BSX) initiated with a Buy at Citi... Bruker (BRKR) initiated with a Buy at Stifel... C.R. Bard (BCR) initiated with a Buy at Citi... Cepheid (CPHD) initiated with a Buy at Stifel... CorMedix (CRMD) initiated with a Buy at Rodman & Renshaw... CoreSite Realty (COR) initiated with a Buy at BB&T... Digital Realty (DLR) initiated with a Buy at BB&T... DuPont Fabros (DFT) initiated with a Hold at BB&T... Duke Realty (DRE) initiated with a Hold at BB&T... Edwards Lifesciences (EW) initiated with a Sell at Citi... Electronic Arts (EA) initiated with an Outperform at Oppenheimer... EyeGate (EYEG) initiated with a Buy at Maxim... Glu Mobile (GLUU) initiated with a Perform at Oppenheimer... Integra LifeSciences (IART) initiated with a Buy at Citi... Intuitive Surgical (ISRG) initiated with a Buy at Citi... Mast Therapeutics (MSTX) initiated with a Buy at Maxim... Medgenics (MDGN) initiated with a Buy at Needham... Novocure (NVCR) initiated with a Buy at Evercore ISI... Prologis (PLD) initiated with a Hold at BB&T... QIAGEN (QGEN) initiated with a Hold at Stifel... Rocket Fuel (FUEL) initiated with a Neutral at Boenning & Scattergood... STAG Industrial (STAG) initiated with an Underweight at BB&T... Stryker (SYK) initiated with a Sell at Citi... Tremor Video (TRMR) initiated with an Outperform at Boenning & Scattergood... VOXX (VOXX) initiated with an Outperform at Oppenheimer... Varian Medical (VAR) initiated with a Neutral at Citi... Yahoo (YHOO) initiated with an Outperform at Boenning & Scattergood... YuMe (YUME) initiated with a Neutral at Boenning & Scattergood... Zimmer Biomet (ZBH) initiated with a Sell at Citi.
11/23/15
PIPR
11/23/15
NO CHANGE
Target $1
PIPR
Overweight
Mast Therapeutics risk/reward attractive into data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Mast Therapeutics after a specialist told his colleague Josh Schimmer that the company's vepoloxamer is "very interesting" and could be "extremely valuable" at reducing acute vaso-occlusive crisis in sickle cell disease patients. Tenthoff views Mast's risk/reward as attractive into the Phase III EPIC trial data, which is expected in Q2 of 2016. He reiterates an Overweight rating on the stock with a $1 price target. Mast shares closed Friday at 39c.
09/21/16
MAXM
09/21/16
DOWNGRADE
MAXM
Hold
Mast Therapeutics downgraded to Hold from Buy at Maxim
09/27/16
COWN
09/27/16
DOWNGRADE
COWN
Market Perform
Mast Therapeutics downgraded to Market Perform from Outperform at Cowen
Cowen analyst Ritu Baral downgraded Mast Therapeutics to Market Perform citing lack of visibility on the path forward after MST-188 missed the primary endpoint in its Phase III trial for sickle cell and discontinued the program.
PHG Philips
$28.84

-0.13 (-0.45%)

08/10/16
UBSW
08/10/16
UPGRADE
UBSW
Buy
Philips upgraded to Buy from Neutral at UBS
08/10/16
UBSW
08/10/16
UPGRADE
UBSW
Buy
Philips upgraded to Buy at UBS
As reported previously, UBS raised Phillips to Buy from Neutral. The firm sees reason for optimism for investors, citing management's targets for margin growth, improved momentum in two key divisions, and the company's position in businesses that are likely to benefit from the secular shift toward value based care.
08/10/16
08/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Outperform from Neutral at Macquarie with analyst Tim Nollen saying he thinks Disney owning this technology gives it commanding position on future content viewership as Bam Tech is a premier OTT streaming technology, allowing Disney to connect directly with consumers. 2. Coach (COH) upgraded to Neutral from Underperform at BofA/Merrill with analyst Lorraine Hutchinson saying management guided margins to 18.5-19%, in line with her 18.5% estimate, reflecting a strategic reduction in the wholesale business, thinks more realistic EBIT targets indicates management has de-risked its outlook, and expects consensus estimates to move towards hers. 3. Philips (PHG) upgraded to Buy from Neutral at UBS with the firm citing management's targets for margin growth, improved momentum in two key divisions, and the company's position in businesses that are likely to benefit from the secular shift toward value based care. 4. Yelp (YELP) upgraded to Outperform from Market Perform at Raymond James, to Neutral from Underperform at BofA/Merrill, to Buy from Hold at Axiom, and to Buy from Neutral at Mizuho. 5. General Dynamics (GD) upgraded to Outperform from Market Perform at Bernstein with Douglas Harned saying shares of General Dynamics are valued at a larger discount to other prime contractors than it has been in the last 14 years and overly discounts weakness in the large cabin business jet market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/23/16
JEFF
08/23/16
DOWNGRADE
Target $58
JEFF
Underperform
ResMed cut to Underperform at Jefferies as peer seen closing gap
As previously reported, Jefferies analyst Anthony Petrone downgraded ResMed (RMD) to Underperform from Hold, noting that the firm's survey and expert calls indicate that those in the field see the company's AirSense10 as still "best-in-class," but Philips' (PHG) Dream has closed the gap while being priced at a discount. Lower Medicare rates that just became effective are pressuring private rates and are seen leading to further consolidation and price pressure, the analyst added. Petrone cut his price target on ResMed shares to $58 from $60.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.